DEVELOPING THE NEXT GENERATION OF MEDICINES THAT TARGET AND ENHANCE THE MICROBIOME Groundwork laid for a future of cultured microbiome therapies targeting specific diseases
INTERVIEW
Associate Professor Sam Forster, CSL Centenary Fellow, Research Group Head
Microbiota and Systems Biology, Hudson Institute of Medical Research
& Team Leader, Australian Microbiome Culture Collection
& Chief Scientific Officer, BiomeBank
Dr Sam Costello,
Co-founder & CEO
BiomeBank
SEGMENT
Filmed in Melbourne and Adelaide | December 2024
Australian Health Journal spoke to Associate Professor Sam Forster, Research Group Head, Microbiota and Systems Biology, Hudson Institute of Medical Research, Team Leader, Australian Microbiome Culture Collection & Chief Scientific Officer, BiomeBank and Dr Sam Costello, Co-Founder and CEO of BiomeBank about the microbiome, partnering and some of the breakthroughs in recent years.
Assoc Prof Forster describes the role of the microbiome, “Every one of us carries thousands of bacteria. Millions of individual cells, and they’re intimately associated with all sorts of sites on our bodies. So our gut is the most common place we think about, but our lungs, our skin, everywhere. Where there’s an interface, the external environment, there’s bacteria and other microbes that actually enable us to interface with the external world. They detect changes and they regulate our immune response.”
This can be really important from a health perspective because they indicate when things are going well, we should have a healthy state or something’s gone wrong, and there is an inflammatory response. This can then be detrimental, or it can help clear a particular condition.
“The microbes we carry are intimately associated with our health.”, says Assoc Prof Forster. He was the founder of the Australian Microbiome Culture Collection at Hudson that now contains over 40,000 bacterial isolates. This provides a resource for further research.
“All of these opportunities are available because we have this vast collection of microbes where we can say this particular combination for you is relevant for this experiment. Taking clinical samples, we then can replicate the host environment using microfluidic organ on-a-chip systems”, says Assoc Prof Forster.
Microbiome therapies involve modifying the body’s microbial communities to improve health. These treatments aim to restore balance to the microbiome, potentially alleviating conditions like inflammatory bowel disease, liver disorders, autoimmune diseases, and certain cancers.
The Hudson Institute of Medical Research and BiomeBank have partnered to advance microbiome-based therapeutics. Their collaboration focuses on identifying key bacteria involved in disease onset and resolution, particularly associated with the gut. By combining their expertise, they aim to develop targeted microbial therapies to treat and prevent diseases by restoring gut microbial ecology.
BiomeBank develops and delivers microbiome therapies. In 2022 BiomeBank was successful in introducing the world’s first approved donor derived microbiome therapy approved in Australia for the treatment of C. Difficile infection.
Through this collaboration, the Hudson Institute and BiomeBank are at the forefront of microbiome research, striving to translate scientific discoveries into effective therapies that can improve patient outcomes.
As Dr Costello states, “We see microbiome therapies evolving in the next few years from predominantly donor derived therapies that are harvested from screened healthy stool donors, towards cultured therapies that can be grown in bioreactors and produced under controlled conditions.”
Assoc Prof Forster has been involved in a number of breakthroughs in culturing previously thought to be unculturable organisms.
-
Elevating Professional Standards in the Medtech and Pharmaceutical Sector
ARCS Australia Ltd, the peak body representing professionals in the MedTech and Pharmaceutical sector, this week announced a series of significant changes at its annual conference.
Dr Tim Boyle, CEO of ARCS Australia Ltd speaking to Australian Health Journal says, “These initiatives are central to strategy to build professionalism within the sector, increase capability and enhance the professional standing of its members.”
-
Jamie Stanistreet talks Medical Technology
Jamie Stanistreet
Retired Managing Director Medtronic Australia and New Zealand
talks Medical Technology in Australia and the Asia-Pacific -
Continuity of Care under COVID-19
Series 3, Episode 1
Under the COVID-19 pandemic, the Australian Healthcare system has handled the public health crisis by monitoring and responding to challenges in supply chains, testing & tracing of new infections and stock piling of essential equipment.
The public has largely responded by practising social distancing, understanding how hand hygiene can spread contagion and recently installing the COVIDSafe mobile application. Public health messaging has been largely effective and literacy improve, to combat the dangers of misinformation.
To open up access to medical advice during the pandemic, in March the Australian government issued MBS item codes for telehealth consultations, for advanced practice nurses as well as GPs and other specialists.
According to AMA President Dr Tony Bartone, as of mid-May 2020, around 10 million Medicare-funded telehealth services have been provided, either over the phone or via video, a significant majority of which have been provided by GPs and other specialists since the Medicare telehealth items were introduced in March.
However in recent months, the health system has mounting concerns on:
- a reduction in general practice visits for testing, investigation or immunisation
- lower rates of elective procedures resuming since being halted
- reduction in laboratory testing
- reduction in treatments and diagnosis of chronic and acute conditions
- access to, and continuing to take medications
Those with pre-existing conditions have been urged to keep appointments and routine treatments to maintain their health.
Industry has taken action such as the newly formed Continuity of Care Collaboration (CCC). The 15 health organisations forming CCC are an Australian first national communication collaboration of Peak Bodies, Industry and Healthcare Organisations coming together to stress the importance for people to continue monitoring their health and maintaining their regular care.
This Australian Health Journal episode on the continuity of care was produced with commentary from the following health industry associations and organisations: APNA – Australian Primary Health Care Nurses Association, RACGP, Medical Technology Association of Australia (MTAA), West Cessnock Medical Practice, Consumers Health Forum of Australia, Medicines Australia
